TICKERNERD
Menu
SOPHSOPHHealthcare · Health Information Services

SOPH Stock Forecast: SOPHiA GENETICS SA Price Predictions for 2026-2027

Last close, 17 Sept 2026
$8.53
+6.96% on the day

The 5 Wall Street analysts covering SOPHiA GENETICS SA hold a median 12-month price target of $9 — +5.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 49 of 100 as at 17 Sept 2026 — in the lower half.

Market cap
$678.9M
Ticker Nerd rank
49 / 100
Median analyst target
$9.00
Analysts covering
5
Revenue$23.3M+27.2% y/y
Operating income−$20.1M
Net income−$22.4M
Free cash flow−$10.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+12.1%
1M
+11.8%
YTD
+82.7%
1Y
+164.1%
From 52W high
−4.4%
From 52W low
+167.4%
$3.19
$8.92
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SOPH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SOPHiA GENETICS SA on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Sept 2026
49 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Accruals
76
Growth
57
Issuance
50
Size
49
Revisions
48
Volatility
36
Quality
26
Value
18

Momentum (99): The shares have been drifting up relative to others.

Value (18): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SOPH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SOPH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Oct 25Jan 26Apr 26Jul 26SOPHHigh $14.00Median $9.00Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $7.00Median $9.00High $14.00

The green dot is the last close — the median target sits +5.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 Aug 2026BTIGMaintainsBuy$8.00 → $9.00
5 Aug 2026HC Wainwright & Co.MaintainsBuy$12 → $14
20 July 2026HC Wainwright & Co.InitiatesBuy$12
20 July 2026HC Wainwright & Co.InitiatesBuy—
15 June 2026BTIGReiteratesBuy$8.00
15 June 2026BTIGReiteratesBuy—
6 May 2026BTIGReiteratesBuy—
15 Apr 2026BTIGMaintainsBuy—
26 Jan 2026GuggenheimMaintainsBuy—
10 Nov 2025BTIGMaintainsBuy—
18 Dec 2024Craig-HallumInitiatesBuy—
7 Aug 2024RBC CapitalMaintainsOutperform—
27 June 2024GuggenheimInitiatesBuy—
6 Mar 2024BTIGMaintainsBuy—
6 Mar 2024RBC CapitalReiteratesOutperform—
12 Jan 2024RBC CapitalReiteratesOutperform—
29 Nov 2023RBC CapitalInitiatesOutperform—
10 May 2023Credit SuisseMaintainsNeutral—
10 May 2023Morgan StanleyMaintainsOverweight—
8 Mar 2023Morgan StanleyMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SOPH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SOPH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 17 Sept 2026, SOPHiA GENETICS SA returned +164.1% against +17.0% for the S&P 500, dividends included.

SOPH vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Oct 25Jan 26Apr 26Jul 26SOPHS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SOPH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

SOPHiA GENETICS SA (SOPH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.2×

Cheaper than 91% of US stocks

Price / sales
8.2×

Cheaper than 16% of US stocks

Price / book
8.6×

Cheaper than 11% of US stocks

EV / EBITDA
−8.8×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
27.2%

Higher than 76% of US stocks

Earnings growth (YoY)
27.2%

Higher than 64% of US stocks

Gross margin
64.6%

Higher than 78% of US stocks

Operating margin
−86.0%

Higher than 14% of US stocks

Net margin
−93.9%

Higher than 6% of US stocks

Returns & dividend
Return on equity
−101.2%

Higher than 13% of US stocks

Return on assets
−24.5%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SOPHiA GENETICS SA (SOPH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • SOPHiA GENETICS SA has a market value of $678.9M and an enterprise value of $633.1M.

  • Revenue in the twelve months to 30 June 2026: $86.2M. The latest quarter grew 27.2% year on year.

  • Net income over the same four quarters: −$80.9M, a −93.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.15.

  • Free cash flow in the twelve months to 30 June 2026: −$50.5M, after $9.2M of capital spending.

  • SOPHiA GENETICS SA spent $0.0 on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 85.1M.

  • Trailing P/E: −7.2×; forward P/E: −16.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • SOPHiA GENETICS SA employs 415 people — $208K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Sept 2026

Data provided by Twelve Data

Peers

SOPH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
SOPHSOPHiA GENETICS SA$678.9M
49
PHRPhreesia, Inc.$619.8M
51
HSTMHealthStream, Inc.$866.0M
95
WEAVWeave Communications, Inc.$586.4M
84
CTEVClaritev Corp.$522.7M
65
NRCNRC Health$470.3M
93
TDOCTeladoc Health, Inc.$1.1B
66

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SOPHiA GENETICS SA — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SOPH news & analysis

When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals

MarketBeat · 27 Aug 2026neutral

MarketBeat published an article examining unusually high trading volume in three small-cap stocks, including SOPHiA GENETICS (SOPH), discussing how volume serves as a measure of conviction behind price moves rather than mere noise.

Why it matters — The piece highlights SOPH as one of three small-caps flagged for notable trading-volume activity, drawing attention to conviction behind its recent price movement.

SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

SOPHiA GENETICS SA published the transcript of its Q2 2026 earnings call via Seeking Alpha. The excerpt confirms the call and transcript took place but provides no details on results or commentary.

Why it matters — SOPH watchers would turn to this transcript for direct management discussion of the company's Q2 2026 financial performance and outlook.

SOPHiA GENETICS Q2 Earnings Call Highlights

MarketBeat · 4 Aug 2026positive

SOPHiA GENETICS reported second-quarter revenue growth of 27% and raised its full-year revenue outlook, citing accelerating U.S. adoption, liquid biopsy momentum, and new biopharma agreements.

Why it matters — The raised outlook and faster growth indicate strengthening demand for SOPHiA's precision medicine software across U.S. and biopharma markets.

SOPHiA GENETICS Reports Second Quarter 2026 Results

PRNewsWire · 4 Aug 2026positive

SOPHiA GENETICS reported Q2 2026 results, with revenue of $23.3 million (up 27% year-over-year), a reported gross margin of 64.6%, a net loss of $22.4 million flat year-over-year, and an adjusted EBITDA loss of $8.8 million improving 27% year-over-year. The company raised its 2026 revenue guidance to $94–96 million, representing 22–24% year-over-year growth.

Why it matters — The report shows accelerating revenue growth, a narrower adjusted EBITDA loss, and an upward revision to full-year guidance, offering a direct update on SOPH's financial trajectory.

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

PRNewsWire · 4 Aug 2026positive

SOPHiA GENETICS announced a new multi-year global collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The agreement advances the development and commercialization of two CDx programs, applying SOPHiA GENETICS's decentralized clinical trial assays and companion diagnostic capabilities to AstraZeneca therapies.

Why it matters — A SOPH watcher would care because the collaboration expands SOPHiA GENETICS's companion diagnostic pipeline and commercial reach through a multi-year partnership with a major pharmaceutical company.

FAQ

Frequently asked questions about SOPH stock

What is the SOPH stock price forecast for 2026-2027?

The 5 Wall Street analysts covering SOPHiA GENETICS SA have a median 12-month price target of $9, with estimates ranging from $7 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SOPH stock a buy right now?

Of the 5 analysts covering SOPHiA GENETICS SA, 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SOPHiA GENETICS SA 49 out of 100 across roughly 4,600 US stocks as at 17 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SOPH?

As at 17 Sept 2026, SOPHiA GENETICS SA ranks 49 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will SOPH stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +5.5% from the last close, and Ticker Nerd's factor model ranks SOPHiA GENETICS SA 49 out of 100 as at 17 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SOPH stock forecast for 2030?

No analyst covering SOPHiA GENETICS SA publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SOPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $14 over the next 12 months.

How has SOPH stock performed over the past year?

SOPHiA GENETICS SA returned +164.1% over the 12 months to 17 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SOPHiA GENETICS SA do?

SOPHiA GENETICS SA Ordinary Shares is the equity of SOPHiA GENETICS, a healthcare technology company focused on data-driven medicine and life sciences research. The company develops cloud-native software that analyzes complex genomic and multimodal healthcare data, helping hospitals, laboratories, and biopharmaceutical organizations generate actionable insights across cancer, rare disorders, and other diagnostic areas.

What is the latest news on SOPH?

The most recent item we track (MarketBeat, 27 Aug 2026): "When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals". MarketBeat published an article examining unusually high trading volume in three small-cap stocks, including SOPHiA GENETICS (SOPH), discussing how volume serves as a measure of conviction behind price moves rather than mere noise.

Company

About SOPHiA GENETICS SA.

SOPHiA GENETICS SA Ordinary Shares is the equity of SOPHiA GENETICS, a healthcare technology company focused on data-driven medicine and life sciences research. The company develops cloud-native software that analyzes complex genomic and multimodal healthcare data, helping hospitals, laboratories, and biopharmaceutical organizations generate actionable insights across cancer, rare disorders, and other diagnostic areas. Its core platform, SOPHiA DDM, supports the interpretation of data from multiple testing modalities, including genomics, radiomics, clinical information, biological data, and digital pathology. SOPHiA GENETICS serves a global network of healthcare and research institutions that use its software to streamline analysis and support more coordinated diagnostic workflows. Headquartered in Rolle, Switzerland, SOPHiA GENETICS operates at the intersection of healthcare, artificial intelligence, and precision medicine, making it an important provider of digital tools for modern clinical and research environments.

CEO Mr. Ross Jordan Muken B.Sc. · 415 employees · Switzerland · https://www.sophiagenetics.com